866-997-4948(US-Canada Toll Free)

PharmaPoint: Obesity - Current and Future Players

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 99 Pages


GlobalData has released its pharma report, PharmaPoint: Obesity Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Investigation of current and future market competition for obesity
  • Competitor assessment 
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. 
  • Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving obesity market 
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. 
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market 
  • Whats the next big thing in the global obesity market landscape? Identify, understand and capitalize
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 11

2 Introduction 12
2.1 Catalyst 13
2.2 Related Reports 14
2.3 Upcoming Related Reports 15

3 Market Outlook 16
3.1 Global Markets 17
3.1.1 Forecast 17
3.1.2 Drivers and Barriers - Global Issues 18

4 Current and Future Players 26
4.1 Overview 26
4.1.1 Medical Device Companies Have the Opportunity to Incorporate Lifestyle Programs 28
4.2 Trends in Corporate Strategy 31
4.3 Company Profiles: Pharmaceutical and Biotech Companies 32
4.3.1 Orexigen Therapeutics 32
4.3.2 Novo Nordisk 35
4.3.3 Takeda Pharmaceutical Company 37
4.3.4 Shionogi 39
4.3.5 Roche Holdings 40
4.3.6 Vivus 42
4.3.7 Arena Pharmaceuticals and Eisai 46
4.4 Company Profiles: Device Companies 49
4.4.1 Allergan 49
4.4.2 Apollo Endosurgery 51
4.4.3 Aspire Bariatrics 53
4.4.4 Agency for Medical Innovation 54
4.4.5 Bariatric Solutions 55
4.4.6 Baronova 56
4.4.7 BaroSense 57
4.4.8 BFKW 59
4.4.9 Cousin Biotech 60
4.4.10 C.R. Bard 61
4.4.11 Endalis Laboratory 62
4.4.12 EndoGastric Solutions 63
4.4.13 EndoSphere 64
4.4.14 EnteroMedics 65
4.4.15 Ethicon Endo-Surgery 67
4.4.16 GI Dynamics 68
4.4.17 Helioscopie 69
4.4.18 IntraPace 71
4.4.19 Medical Innovation Development 72
4.4.20 MetaCure 73
4.4.21 Obalon Therapeutics 74
4.4.22 ReShape Medical 76
4.4.23 Spatz Medical 77
4.4.24 ValenTx 78

5 Appendix 79
5.1 Bibliography 79
5.2 Abbreviations 82
5.3 Research Methodology 84
5.4 Forecasting Methodology 84
5.4.1 Percent Drug-Treated Obesity Patients 85
5.4.2 Drugs Included in Each Therapeutic Class 85
5.4.3 Launch and Patent Expiry Dates 86
5.4.4 General Pricing Assumptions 86
5.4.5 Individual Drug Assumptions 87
5.4.6 Generic Erosion 91
5.4.7 Pricing of Pipeline Agents 91
5.5 Physicians, Specialists, and Payers Included in This Study 92
5.6 About the Authors 95
5.6.1 Analysts 95
5.6.2 Therapy Director - CVMD and Infectious Disease 96
5.6.3 Director - Medical Devices 96
5.6.4 Global Head of Healthcare 97
5.7 About GlobalData 98
5.8 Disclaimer 98

List of Table


Table 1: Global Sales Forecasts ($m) for Obesity, 2012-2022 17
Table 2: Global Obesity Market - Drivers and Barriers, 2012-2012 19
Table 3: Key Companies in the Obesity Market, 2013 30
Table 4: Orexigens Disease/Therapy Portfolio Assessment, 2013 34
Table 5: Orexigen Therapeutics SWOT Analysis, 2013 35
Table 6: Novo Nordisks Disease/Therapy Portfolio Assessment, 2013 36
Table 7: Novo Nordisk SWOT Analysis, 2013 37
Table 8: Takedas Disease / Therapy Portfolio Assessment, 2013 38
Table 9: Takeda SWOT Analysis, 2013 38
Table 10: Shionogis Disease/Therapy Portfolio Assessment, 2013 39
Table 11: Shionogi SWOT Analysis, 2013 40
Table 12: Roche Holdings Disease/Therapy Portfolio Assessment, 2013 41
Table 13: Roche Holdings SWOT Analysis, 2013 42
Table 14: Vivus Disease/Therapy Portfolio Assessment, 2013 45
Table 15: Vivus SWOT Analysis, 2013 46
Table 16: Arena Pharmaceuticals Disease/Therapy Portfolio Assessment, 2013 48
Table 17: Arena and Eisai SWOT Analysis, 2013 48
Table 18: Company Profile - Allergan 50
Table 19: Allergan SWOT Analysis 51
Table 20: Company Profile - Apollo Endosurgery 52
Table 21: Apollo Endosurgery SWOT Analysis 52
Table 22: Company Profile - Aspire Bariatrics 53
Table 23: Aspire Bariatrics SWOT Analysis 53
Table 24: Company Profile - AMI 54
Table 25: AMI SWOT Analysis 55
Table 26: Company Profile - Bariatric Solutions 55
Table 27: Bariatric Solutions SWOT Analysis 56
Table 28: Company Profile - Baronova 56
Table 29: Baronova SWOT Analysis 57
Table 30: Company Profile - BaroSense 58
Table 31: BaroSense SWOT Analysis 58
Table 32: Company Profile - BFKW 59
Table 33: BFKW SWOT Analysis 59
Table 34: Company Profile - Cousin Biotech 60
Table 35: Cousin Biotech SWOT Analysis 61
Table 36: Company Profile - CR Bard 61
Table 37: CR Bard SWOT Analysis 62
Table 38: Company Profile - Endalis Laboratory 62
Table 39: Endalis Laboratory SWOT Analysis 63
Table 40: Company Profile - EndoGastric Solutions 63
Table 41: EndoGastric Solutions SWOT Analysis 64
Table 42: Company Profile - EndoSphere 64
Table 43: EndoSphere SWOT Analysis 65
Table 44: Company Profile - EnteroMedics 66
Table 45: EnteroMedics SWOT Analysis 66
Table 46: Company Profile - Ethicon Endo-Surgery 67
Table 47: Ethicon Endo-Surgery SWOT Analysis 68
Table 48: Company Profile - GI Dynamics 69
Table 49: GI Dynamics SWOT Analysis 69
Table 50: Company Profile - Helioscopie 70
Table 51: Helioscopie SWOT Analysis 70
Table 52: Company Profile - IntraPace 71
Table 53: IntraPace SWOT Analysis 72
Table 54: Company Profile - Medical Innovation Development 72
Table 55: Medical Innovation Development SWOT Analysis 73
Table 56: Company Profile - MetaCure 74
Table 57: MetaCure SWOT Analysis 74
Table 58: Company Profile - Obalon Therapeutics 75
Table 59: Obalon Therapeutics SWOT Analysis 75
Table 60: Company Profile - ReShape Medical 76
Table 61: ReShape Medical SWOT Analysis 76
Table 62: Company Profile - Spatz Medical 77
Table 63: Spatz Medical SWOT Analysis 77
Table 64: Company Profile - ValenTx 78
Table 65: ValenTx SWOT Analysis 78
Table 66: Key Launch Dates 86
Table 67: Key Patent Expiries 86

List of Chart


Figure 1: Global Sales for Obesity by Region, 2012-2022 18
Figure 2: Company Portfolio Gap Analysis in Obesity, 2012-2022 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *